MDWD (MDWD) Stock Price & Analysis
MDWD (MDWD) rose 0.63% to USD 14.3 as of June 10, 2026 at 08:26 UTC, according to Nexqual real-time market data.
MDWD last closed at USD 14.21; the session ranged USD 14.1–14.4 on volume of 91,523 shares. Market capitalization is $183.79M, with a 52-week range of USD 13.54–21.32 (NGM). Source: Nexqual, June 10, 2026 at 08:26 UTC.
Key Statistics (as of June 10, 2026 at 08:26 UTC)
| Price | USD 14.3 |
|---|---|
| Change | ▲ 0.63% (up) |
| Previous Close | USD 14.21 |
| Open | USD 14.2 |
| Day Range | USD 14.1 – 14.4 |
| 52-Week Range | USD 13.54 – 21.32 |
| Volume | 91,523 shares |
| Market Cap | $183.79M |
| Exchange | NGM |
Technical Analysis (MDWD)
Nexqual's technical model rates MDWD "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 08:26 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.06 (neutral) |
| vs SMA50 | Below (USD 16.31) |
| MACD | -0.74 (negative) |
Analyst Ratings (MDWD)
Wall Street analysts rate MDWD "Strong Buy" based on 6 analysts, with a mean price target of USD 30.17 (range USD 22–36), per Nexqual as of June 10, 2026 at 08:26 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 30.17 |
| High Target | USD 36 |
| Low Target | USD 22 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (MDWD)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.77 |
| Revenue Estimate | $2.59M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.23 vs est -0.66 ▲ beat |
| 2025-12-31 | USD -0.56 vs est -0.61 ▲ beat |
| 2025-09-30 | USD -0.24 vs est -0.83 ▲ beat |
| 2025-06-30 | USD -1.23 vs est -0.57 ▼ miss |
Source: Nexqual, June 10, 2026 at 08:26 UTC.
Financials & Fundamentals (MDWD)
| Total Revenue | $14.48M |
|---|---|
| Revenue Growth (YoY) | -62.70% |
| Gross Margin | +19.61% |
| Operating Margin | -541.02% |
| Profit Margin | -180.30% |
| ROE | -71.82% |
| Debt / Equity | 19.62 |
| Current Ratio | 2.41 |
| Total Cash | $44.65M |
| Total Debt | $8.13M |
| Free Cash Flow | $-18.44M |
Source: Nexqual, June 10, 2026 at 08:26 UTC.
Financial Health Score (MDWD)
Nexqual rates MDWD's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 08:26 UTC.
| Growth | Critical — Revenue -16% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $45M cash vs $8M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$18M, burning cash |
| Efficiency | Critical — ROE -72%, ROA -23.5% |
Ownership (MDWD)
| Insider Ownership | +15.86% |
|---|---|
| Institutional Ownership | +58.24% |
| Shares Outstanding | 12.85M |
| Float | 8.91M |
| Short % of Float | +14.47% |
Source: Nexqual, June 10, 2026 at 08:26 UTC.
Leadership (MDWD)
MDWD is led by Ofer Gonen B.Sc. (age 52), Chief Executive Officer, per Nexqual as of June 10, 2026 at 08:26 UTC.
| Chief Executive Officer | Ofer Gonen B.Sc. (age 52) |
|---|---|
| Chief Financial Officer | Hani Luxenburg (age 51) |
| COO & Chief Commercial Officer | Shmulik Hess (age 51) |
| Vice President of Manufacturing Science & Technology | Liron Gal |
| Executive Vice President of Strategy & Corporate Development | Barry J. Wolfenson (age 58) |
Major Backers & Investors (MDWD)
Notable institutional backers of MDWD include Investor AB, Price (T.Rowe) Associates Inc, Yelin Lapidot Holdings Management Ltd., according to Nexqual as of June 10, 2026 at 08:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Investor AB | 6.83% |
| Price (T.Rowe) Associates Inc | 6.25% |
| Yelin Lapidot Holdings Management Ltd. | 5.98% |
| Rosalind Advisors, Inc. | 5.87% |
| Meitav Investment House Ltd. | 2.91% |
| T. Rowe Price | 2.72% |
| Sphera Funds Management Ltd. | 2.14% |
| Silverberg Bernstein Capital Management LLC | 1.57% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.67% |
Source: Nexqual, June 10, 2026 at 08:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KMDA | Kamada Ltd. | USD 7.24 | ▲ 0.98% |
| GLMD | Galmed Pharmaceuticals Ltd. | USD 0.52 | ▼ 25.03% |
| URGN | UroGen Pharma Ltd. | USD 28.18 | ▲ 4.95% |
| SLGL | Sol-Gel Technologies Ltd. | USD 76.22 | ▼ 2.26% |
| CLGN | CollPlant Biotechnologies Ltd. | USD 0.37 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:26 UTC. This page is informational and not investment advice.